Investor relations

Investing in the future of cardiac diagnosis

Phantomics is a medical AI company spun out of Yonsei University Severance Hospital. Our cleared products turn cardiac MRI and CT into fast, standardized, one-click analysis, and they are already used in hospitals across Korea, Asia, the U.S. and Europe. This page introduces the company to international investors and strategic partners.

#1
Cardiovascular disease is the leading cause of death worldwide (WHO)
30 min → 2 min
Cardiac MRI analysis time with Myomics, as reported by hospital users
5–10 min
Angiomics ER analysis time for emergency chest-pain triage
95%+
Reported accuracy of Myomics cardiac function and tissue analysis

Phantomics at a glance

Founded
September 2019, Seoul — faculty spin-out from Yonsei University Severance Hospital
Offices
Seoul, South Korea (HQ) · Cambridge/Boston, USA (subsidiary since 2024)
Products
Myomics® (cardiac MRI AI) · Angiomics® / Angiomics ER (cardiac CT AI triage)
Regulatory
U.S. FDA 510(k) · Korea MFDS (Class 2 and Class 3) · Japan PMDA · Taiwan FDA · Thai FDA · Malaysia MDA
Quality
EN ISO 13485:2016 · GMP certified
Adoption
20+ major hospitals in Korea · 19 international medical institutions
Intellectual property
20 patents
Recognition
CES 2024 Innovation Award · FIX 2024 Innovation Awards Grand Prize · KHF 2025 Innovation Award · Seoul Awards 2024

Why Phantomics

Six reasons we believe Phantomics is positioned to lead AI-driven cardiovascular diagnosis.

01

A large, unmet clinical need

Cardiovascular disease is the world's leading cause of death, claiming about 17.9 million lives a year according to the WHO. Cardiac MRI and CT are the most informative non-invasive tests, but long scan and reading times and scarce expertise keep them underused. Automation unlocks that capacity.

02

Proven, clinically validated technology

Myomics reduces cardiac MRI analysis from 30 minutes or more to a few minutes, with quantitative results standardized against reference ranges. Our methods are documented in more than 20 peer-reviewed publications with partners such as Severance Hospital, Asan Medical Center and RSNA journals.

03

A regulatory moat across six markets

Clearances from the U.S. FDA, Korea's MFDS (including the Class 3 approval of Angiomics ER), Japan's PMDA, Taiwan, Thailand and Malaysia, plus ISO 13485 certification, represent years of clinical and regulatory work that new entrants must repeat.

04

Commercial traction and blue-chip partners

Myomics is in routine use at more than 20 tertiary hospitals in Korea and at 19 institutions abroad. Strategic agreements with GE HealthCare Korea, Siemens Healthineers, Getz Healthcare (ASEAN distribution), K-MEDI HUB and leading university hospitals extend our reach.

05

An expanding product pipeline

Beyond Myomics, Angiomics ER brings AI triage to emergency chest pain, a 10-minute non-contrast cardiac MRI protocol targets the premium health-screening market, and deep-learning models that predict future cardiac events point toward prognostic AI.

06

Global expansion already under way

A U.S. subsidiary in Boston, Japanese PMDA approval and JRS certification, and distribution partners across Southeast Asia give Phantomics a path into the largest imaging markets, supported by Korea's TIPS global marketing and export programs.

Funding and support

2022

Series A

Led by Daily Partners and Bluepoint Partners.

2024

Super Gap 1000+ and TIPS Global Marketing

Selected for the Ministry of SMEs and Startups' Super Gap 1000+ program and the TIPS global marketing program supporting overseas expansion.

2025

Seoul-type Strong SME

Two-year support agreement with the Seoul Metropolitan Government (2025–2026).

Phantomics welcomes conversations with financial and strategic investors, distribution partners and healthcare systems. Please use the form below or write to contact@phantomics.io with "Investor inquiry" in the subject line.

Talk to our investor relations team

Request the company presentation, schedule a call with management or ask about partnership opportunities.

Investor inquiry

Consent for collection and use of personal information (required)

For the purpose of the Contact Us service, Phantomics collects and uses the following personal information. Items: name, e-mail, institution or company name, job title, country. Purpose: responding to inquiries. Retention: up to 3 years from the date of submission unless a longer period is required by law. You may refuse consent; however, refusal may limit the service.

This page contains forward-looking statements based on current expectations and publicly available information about Phantomics Inc. It is provided for information only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Figures such as analysis times and accuracy are as reported by the company and its clinical partners and may vary by site and protocol.

⚡ Made with pagesss